Delving into the Latest Updates on In Therapeutics Co. Ltd. with Synapse

A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers

This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia patients, and to assess the relative bioavailability of Mesylate vs Hydrochloride salt capsules of iN1011-N17 in Healthy volunteers.

开始日期2022-11-11

申办/合作机构

In Therapeutics Co. Ltd.初创企业

ACTRN12622001300763 / Recruiting临床1期

A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers

开始日期2022-08-24

申办/合作机构

In Therapeutics Co. Ltd.初创企业

ACTRN12620001253998 / Recruiting临床1期

A randomized, double-blind, placebo-controlled, single-ascending dose Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics properties of iN1011N17 after oral administration in healthy volunteers

开始日期2020-11-16

申办/合作机构

In Therapeutics Co. Ltd.初创企业

100 项与 In Therapeutics Co. Ltd. 相关的临床结果

登录后查看更多信息

0 项与 In Therapeutics Co. Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 In Therapeutics Co. Ltd. 相关的药物交易

登录后查看更多信息

100 项与 In Therapeutics Co. Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

6

4

临床前

临床1期

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

DWP-17061 ( Nav1.7 )	疱疹后神经痛更多	临床1期
iN1213-N17 ( Nav1.7 )	神经痛更多	临床前
iN1012-N17 ( Nav1.7 )	术后疼痛更多	临床前
iN-3211-K23 ( Kv7.2 x Kv7.3 )	阿尔茨海默症更多	临床前
iN-3111-K23 ( Kv7.2 x Kv7.3 )	癫痫更多	临床前